Blue­bird snags more out­comes-based cov­er­age for its $3M+ sick­le cell gene ther­a­py

A sec­ond out­comes-based agree­ment with an uniden­ti­fied pay­er is now in the books for blue­bird bio’s new $3.1 mil­lion sick­le cell gene ther­a­py, the com­pa­ny said Thurs­day in an SEC fil­ing.

The an­nounce­ment brings the cu­mu­la­tive to­tal of cov­ered lives for the ther­a­py known as Lyf­ge­nia to ap­prox­i­mate­ly 200 mil­lion peo­ple, sug­gest­ing that the biotech has locked up broad cov­er­age from ma­jor in­sur­ers af­ter fac­ing doubts about its com­mer­cial strat­e­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER